Research SquareJune 11, 2026Sarah A Limbacher, Sarah Bird, Julia Wrobel et al.
preprint
Abstract Introduction: Studies have shown that tetrahydrocannabinol (THC) consumption can acutely increase heart rate (HR) regardless of the percent concentration of the product consumed, mode of consumption (e.g. flower, edibles, concentrate), and tolerance. Prior studies have found that the magnitude of this effect is slightly larger in inhaled products, however few purposeful studies on HR...
Cannabis-induced psychosis is a serious psychiatric condition and is associated with chronic and prolonged cannabis use. The chronic use of cannabis often results in significant cognitive, behavioural and psychosocial impairment. The present case study examined the case history of SM. He was a 45-year-old married male with a twenty-year history of cannabis dependence. He was presented with...
Frontiers in PsychiatryJune 10, 2026Justyna Śniadach, Sylwia Szymkowiak, Przemysław Osip et al.
Background: Cannabis use has increased across Europe over the last decade, accompanied by growing availability of high-potency THC products and rising psychiatric presentations. Despite these trends, European countries differ substantially in monitoring systems, clinical preparedness and public health responses. These disparities are especially visible between Western Europe, which has more...
Anxiety disorders are among the most prevalent and disabling mental health conditions and are associated with impairments in quality of life (QoL). Previous studies have examined medicinal cannabis for anxiety and QoL using short-term follow-up or cross-sectional surveys. However, there is little longitudinal qualitative research examining how patients experience QoL changes. To explore the...
Debates em PsiquiatriaJune 9, 2026L. Baldaçara, G. A. Rocha, Roberto Mendes Dos Santos et al.
Introduction: Cannabis use and the availability of high-potency cannabis-derived products and synthetic cannabinoids have increased worldwide, contributing to a growing burden of emergency presentations involving intoxication, agitation, psychosis, cardiovascular complications, and other acute toxic effects. Objective: This review aimed to update the clinical approach to emergencies related to...
Cannabis use is increasing across the United States, creating clinical, ethical, and educational challenges for Psychiatric-Mental Health Nurse Practitioners (PMHNPs). The evolving legal landscape, including the 2025 federal directive to reclassify cannabis from Schedule I to Schedule III, expands research opportunities while maintaining regulatory complexity. Evidence shows cannabidiol (CBD)...
OBJECTIVE Cannabis use is a known risk factor for psychosis, but it remains unclear whether cannabis-associated psychosis (CAP) differs meaningfully from non-cannabis-associated psychosis (NCAP) in clinical presentation, biology, or illness course. The objective of this study was to characterize the presentation and course of first-episode psychosis with and without cannabis exposure. METHODS...
Global shifts towards the liberalisation of cannabis policies have increased the potency of cannabis products, alongside their accessibility, diversity, and the number of inexperienced cannabis consumers. There is a lack of systematic evidence on the subjective effects of cannabis' main psychoactive compound, Δ9-tetrahydrocannabinol (THC). We systematically reviewed and meta-analysed data from...
Kratom ( Mitragyna speciosa ) is a psychoactive botanical with a long history of use in Southeast Asia and growing uptake in the United States for its analgesic, stimulant, and mood-altering properties. The evidence base remains limited, and retail products vary widely in composition and potency. This narrative review highlights what is known about kratom's pharmacology and suggests a practical...
NeuropsychopharmacologyJune 2, 2026Sarah A Thomas, Meghan A Gonsalves, Gillian LeBlanc et al.
Approximately 10-20% of U.S. adolescents report past-year cannabis use (CU). Although regular CU beginning in adolescence is expected to blunt dopamine-related neurophysiology, this hypothesis has not been tested in adolescents due to methodological limitations. However, neurophysiology contributing to dopamine can be noninvasively indexed via subcortical tissue iron measured with magnetic...
Cannabis products are widely accessible, yet adult presentations after unintentional ingestion of psychoactive Δ9-tetrahydrocannabinol (THC), synthetic cannabinoids, or adulterated cannabidiol (CBD) remain poorly described. This scoping review summarizes adult unintentional THC exposures among adults seeking medical care with confirmed ingestion, verified either by positive THC urine drug...
Cannabis terpenes are widely recognized for shaping the plant's aromatic and sensory profiles. Yet, their pharmacological role in cannabis is less established. Recent work demonstrated that several cannabis terpenes can activate cannabinoid receptors type 1 and 2 (CB1R and CB2R) as low-efficacy agonists, raising the possibility that they may also modulate the activation at these receptors by...
Introduction Cannabis consumption has rapidly increased in Delaware due to the legalization of recreational use. There is limited research, however, investigating the links between cannabis use and cognition in older adults. Objectives The objective of this study is to represent the first population-level analysis of cannabis use and subjective cognitive decline (SCD) in older adults in First...
Introduction The expanding use of cannabis, in both recreational and medicinal contexts, highlights a dual reality of therapeutic potential and clinical concern. On one side, cannabinoids show promising medical applications, including chronic pain relief and antiemetic effects. On the other, cannabis consumption is linked to a broad spectrum of adverse outcomes. Psychiatric effects range from...
European PsychiatryJune 1, 2026L. Jishkariani, D. Zurabashvili, K. Gigolashvili et al.
Introduction Cannabis decriminalization raises concerns about its psychiatric impact, particularly on psychosis risk. As cannabis became decriminalized in Georgia in 2018, questions emerged regarding changes in substance-related and acute psychotic disorders. Examining these trends is essential to guide prevention, treatment, and policy in a shifting drug landscape. Objectives This study aims...
Introduction Following Thailand’s cannabis decriminalization in 2022, a marked rise in psychiatric presentations related to cannabis use has been observed nationwide. While international evidence has linked high-THC cannabis exposure to psychosis and substance-induced disorders, empirical data from Asian settings remain limited. This late-breaking study provides updated national trends and...
ObjectiveThis study examined stimulant and medicinal cannabis prescribing in individuals before and after referral to an early psychosis (EP) service in Queensland, Australia.MethodsA retrospective review of 220 consecutive EP referrals (2019-2023) was conducted, extracting data on stimulant and medicinal cannabis prescriptions from clinical records. Longitudinal prescribing patterns were...
Introduction In India’s context of an unregulated drug supply, psychosis is often attributed to cannabis based on patient history alone. However, the widespread contamination of substances with synthetic cannabinoids, opioids, and novel psychoactive substances (NPS) precipitates severe and atypical psychotic presentations that are frequently misdiagnosed as Cannabis-Induced Psychosis (CIP)....
NeuropharmacologyJune 1, 2026Evan C Smith, Christos Iliopoulos-Tsoutsouvas, Markos-Orestis Georgiadis et al.
Despite being the most prevalently abused illicit drug class, the neurochemical effects of cannabinoids (CBs) in key reward-related brain regions are not fully understood. Here, we used in vivo microdialysis combined with liquid chromatograph mass spectrometry to delineate how single, intraperitoneal injections of delta-9-tetrahydrocannabinol (Δ9-THC), and synthetic partial (AM11101) and full...
Long-chain polyunsaturated fatty acids (LC-PUFAs) are crucial for brain development, with ω-3 species supporting neuronal membrane architecture, synaptogenesis and cognitive maturation, and ω-6 species linking lipid metabolism to neuronal signalling via the endocannabinoid system (ECS), the network of receptors, lipid mediators, and enzymatic pathways that orchestrate neurodevelopmental...